RxDoctor Payments Data

Christina Olivetti, OD

Optometrist · Phoenix, AZNPI 1225094774

Payments from drug & device makers

$2,806in general payments, 2019–2025

Across 103 payments — averaging $27.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$885
  • Bausch & Lomb Americas Inc.$264
  • Alcon$261
  • Apellis Pharmaceuticals, Inc.$197
  • Amgen$161
  • Kala Pharmaceuticals, Inc.$143
  • plus $895 from 16 others

What the payments were for

  • Speaking & faculty fees$231%
  • Travel & lodging$231%
  • Food & beverage$2,76098%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,806 in reported general payments places this provider in the 85th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$243,733
Medicare patients
1,135
Services billed
2,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$64,701
XdemvyLotilaner21$39,116
LumiganBimatoprost59$34,330
MieboPerfluorohexyloctane/Pf41$32,030
XiidraLifitegrast14$25,388
Latanoprost930$12,320
Travoprost44$9,237
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$7,943
Cyclosporine12$6,010
SimbrinzaBrinzolamide/Brimonidine Tart25$5,420
Brimonidine Tartrate251$3,327
Doxycycline Hyclate20$2,997
CombiganBrimonidine Tartrate/Timolol11$2,926
Dorzolamide Hcl137$2,838
Prednisolone Acetate52$2,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$885$101,957115 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$264$57,41855 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$77$39,11621 claims
AlconSimbrinza$261$5,42025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →